P2.09. Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY) - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Laura Mezquita
Meta Tag
Speaker Laura Mezquita
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
first-generation TKI
metastatic non-small cell lung cancer
EGFR mutations
progression-free survival
global strategy
overall survival
response rate
tumor burden
clinical profile
Powered By